Navigation Links
New target to stop cancer's spread discovered by Georgia State scientists

Disrupting a key interaction between two types of proteins in cells inhibits the spread of cancerous cells, providing researchers with a new pathway toward developing cancer-fighting drugs, according to new findings by Georgia State University scientists.

Cell migration is essential for the spread of cancerous cells, also known as metastasis, as well as for other diseases. The research team in the labs of Zhi-Ren Liu, professor of biology, and Jenny Yang, professor of biochemistry, studied the interaction of two molecules, p68 RNA helicase and calcium-calmodulin.

Interrupting the interaction between p68 and calcium-calmodulin, which is essential for cell migration, inhibited metastasis.

The findings were recently published in Nature Communications.

"Cancer, at its primary site, will not necessary kill," Liu explained. "Cancer kills by multi-site metastasis. If we are able to disrupt this interaction, we will able to inhibit cancer metastasis. The research indicates that the interaction is absolutely required for all cell migration, and we suspect it may not be limited to cancerous-type cells. It may be a general phenomenon for all cell types."

Calcium-calmodulin is an important protein, acting like a messenger to turn different proteins on and off, said Yang, whose lab focuses on calcium's role in biological processes.

"Calmodulin is a very interesting protein and it interacts with many different systems in response to calcium level changes," she said. "We have demonstrated a new target. There are new ways possible to modulate calcium signaling as a way to treat diseases."

Because cell migration is a common phenomenon that is not only normal, but also related to diseases, there are impacts on treating other diseases, Liu said, from inflammation to neurodegenerative diseases and heart disease.


Contact: Jeremy Craig
Georgia State University

Page: 1

Related medicine news :

1. High Complexity Laboratory Testing Supports New Targeted Therapies for Leukemias and Lymphomas
2. Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients
3. Astrocytes identified as target for new depression therapy
4. LSUHSC research provides new drug target for Her-2 related breast cancer
5. Drug targets hard-to-reach leukemia stem cells responsible for relapses
6. Researchers identify new target for common heart condition
7. Targeting use of acid-suppressants in hospital patients
8. Ovarian cancer stem cell study puts targeted therapies within reach
9. Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment
10. Targeted gene silencing drugs are more than 500 times more effective with new delivery method
11. UGA research offers new targets for stroke treatments
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: